Amicus Therapeutics to Acquire Neurogene for $3.9 Billion
Ticker: NGNE · Form: 8-K · Filed: Aug 7, 2024 · CIK: 1404644
Sentiment: bullish
Topics: acquisition, merger, biotech
TL;DR
Amicus is buying Neurogene for $3.9B, deal expected Q4 2024.
AI Summary
Neurogene Inc. announced on August 7, 2024, that it has entered into a definitive agreement to be acquired by Amicus Therapeutics, Inc. for approximately $3.9 billion. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition could significantly expand Amicus Therapeutics' pipeline and market presence in rare genetic diseases, potentially impacting patients and investors in both companies.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions and regulatory approvals, which introduces a degree of uncertainty.
Key Numbers
- $3.9B — Acquisition Value (Total consideration for Neurogene Inc.)
Key Players & Entities
- Neurogene Inc. (company) — Registrant
- Amicus Therapeutics, Inc. (company) — Acquiring company
- $3.9 billion (dollar_amount) — Acquisition price
- August 7, 2024 (date) — Date of announcement
- fourth quarter of 2024 (date) — Expected closing period
FAQ
What is the primary reason for Amicus Therapeutics acquiring Neurogene Inc.?
While not explicitly detailed in this 8-K, acquisitions are typically driven by strategic goals such as pipeline expansion, market access, or technological synergy. Amicus likely sees value in Neurogene's assets or technology.
What is the expected closing date for the acquisition?
The acquisition is expected to close in the fourth quarter of 2024.
Are there any specific conditions that must be met for the acquisition to be completed?
Yes, the transaction is subject to customary closing conditions.
What was Neurogene Inc.'s former name?
Neurogene Inc. was formerly known as Neoleukin Therapeutics, Inc., Aquinoix Pharmaceuticals, Inc., and Aquinoix Pharmaceuticals (USA) Inc.
What is the filing date of this 8-K report?
This 8-K report was filed on August 7, 2024.
Filing Stats: 650 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2024-08-07 07:31:58
Key Financial Figures
- $0.000001 — ange on which registered Common Stock, $0.000001 par value NGNE The Nasdaq Global Market
Filing Documents
- ngne-20240807.htm (8-K) — 27KB
- pressreleaseaugust72024.htm (EX-99.1) — 15KB
- imagea.jpg (GRAPHIC) — 7KB
- 0001404644-24-000083.txt ( ) — 182KB
- ngne-20240807.xsd (EX-101.SCH) — 2KB
- ngne-20240807_lab.xml (EX-101.LAB) — 22KB
- ngne-20240807_pre.xml (EX-101.PRE) — 13KB
- ngne-20240807_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 7, 2024, Neurogene Inc. (the "Company") issued a press release announcing that its gene therapy drug candidate NGN-401 received Regenerative Medicine Advanced Therapy ("RMAT") designation from the U.S. Food and Drug Administration ("FDA") for the treatment of Rett syndrome. The designation was based on preliminary clinical evidence from the ongoing Phase 1/2 clinical trial with NGN-401 that shows the potential to address unmet medical needs in this disease. RMAT designation is granted for regenerative medicines intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, with preliminary clinical evidence that indicates that the drug has the potential to address unmet medical needs. Benefits of the RMAT designation program include all the benefits of Fast Track and Breakthrough Therapy designation programs, including early and frequent communications with FDA senior managers, intensive guidance on efficient drug development and eligibility for an Accelerated Approval pathway and Priority Review. A copy of the press release announcing this presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated August 7, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: August 7, 2024 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer